FMS News Today: Stay Updated with the Latest Fresenius Medical Care AG & Co. KGaA News in Real Time
Find FMS news now at Meyka AI. Stay informed with the latest Fresenius Medical Care AG & Co. KGaA stocks updates, including price news, market analysis, and expert insights.
Thailand’s Princess Bajrakitiyabha Dies at 47 After Three Years in Coma
Princess Bajrakitiyabha of Thailand dies at 47 after 3.5 years in coma from heart infection, creating succession uncertainty.
German Pensions Rise 4.24% from July 1, 2026
Germany’s Bundesrat approves 4.24% pension increase starting July 1, 2026. Standard retirees gain €77.85 monthly as wage growth outpaces inflation.
Thai Princess Bajrakitiyabha Dies After 3.5 Years in Coma, June 12
Thai Princess Bajrakitiyabha, 47, dies after 3.5-year coma following cardiac arrest. King’s eldest daughter had diplomatic and legal career.
Sydney Childcare Worker Faces Sentencing on Abuse Charges, June 12
David William James pleaded guilty to 11 charges related to child abuse material at six Sydney childcare centres.
Hong Kong MPF Contribution Limits Set to Rise, June 12
MPF contribution limits may rise to HK$40,000 monthly income cap from July 2026, with lower earners exempt above HK$10,500.
Swiss Army Truck Overturns in Solothurn, Nine Soldiers Injured June 12
Swiss Army armored transport vehicle (GMTF) overturned near Hauenstein, Solothurn on June 11, injuring nine soldiers. Military justice investigating.
Hong Kong Official Struggles in Hospital Pay Hearing, June 12
Hospital Authority executives earned 8,260 million HKD over five years while front-line staff received minimal raises amid pay equity concerns.
India’s Food Safety Tests Fail 1 in 6 Samples in FY26, June 12
India’s food safety regulator reports 1 in 6 samples failed tests in FY26, highlighting the need for stronger enforcement and safer food practices.
Ono Pharma Seeks Japan Approval for OPDIVO Thyroid Cancer Treatment, June 12
Ono Pharma seeks Japan approval for OPDIVO in unresectable anaplastic thyroid cancer after NAVIGATION trial achieved 47.6% response rate.